A S X A N N O U N C E M E N T Quarterly Activity report Q1 FY27 Thursday, 29 October 2026 Recent activity • Progressing the LAM development program with CYV-101 nebulisation preclinical feasibility and preliminary safety and tolerability studies • Signed an agreement with Polarian to use...